Fosun Pharmaceutical: the holding subsidiary started the phase II clinical study on the treatment of fs-1502 for non-small cell lung cancer
Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. launched phase II clinical research on fs-1502 (i.e. recombinant HER2 humanized monoclonal antibody monomethylorestatin f coupling agent for injection) for the treatment of non-small cell lung cancer (NSCLC) in China (excluding Hong Kong, Macao and Taiwan).
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing Jun 10, 2022 11:19 AM
· Automotive
Charging pile plate continued to rise, accumulating into electronic sealing limit
Jan 30, 2026 06:00 PM
Dec 11, 2023 08:49 PM
Nov 16, 2022 05:19 PM
Nov 10, 2022 02:39 PM
Briefing May 23, 2022 06:28 AM
Domestic A + G listed companies will increase to 12, and the Swiss stock exchange may welcome Chinese enterprises for the first time in the second half of the year
Healthcare
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Briefing May 10, 2022 07:10 PM
China Eastern Airlines: it is proposed to raise no more than 15 billion yuan for the project of introducing 38 aircraft
Briefing Apr 02, 2022 06:28 PM
Sanya, Hainan: suspend the operation of road passenger transport lines, tourism passenger transport, buses, etc
See more
Read next
Insight
In-depth
Insight
In-depth
Mobility · Analysis
Another Chinese EV Startup Turns Profitable in China’s RMB 5 Trillion Auto Market
May 06, 2026 12:05 PM
Insight
In-depth
Technology, New Energy · Interview
AIFC Governor Renat Bekturov: Kazakhstan Is the Gateway for Chinese Capital Moving West
Apr 30, 2026 03:33 PM